Once in a while it may happen that researchers in the medical field reach a point when the results of a certain project may be transferred into clinical use. It is then understandable that the researchers want to share this information with other professionals as quickly as possible, either in an abstract or in a lecture. However, by doing so, they may most efficiently spoil the opportunity of the discovery to reach the patient. In order to convert an idea or discovery into clinical use, there must always be a commercial partner involved that may handle the commercialization of the product and provide the financial investments that are inevitable to reach this goal. However, a company will seldom undertake such an endeavor unless they can protect the rights of their product. For this purpose the immaterial rights, also called intellectual property and usually controlled by a patent, is crucial. No company can invest millions of dollars and then find that a similar product is being produced at lesser cost by a competing business, thereby limiting the possibility to regain their investment or even to make a profit. To be able to patent an idea or discovery there are certain requirements that must be fulfilled; -the idea must be new, -it must be useful, -it must be based on a technique or knowledge not available to everybody, i.e. to have a technical height, -and it must not be public information. The last point is in fact harder to fulfill than it may seem at first glance. An idea under these circumstances is considered to be public simply if it has been related to a third party without a secrecy agreement. To present the idea at a congress or a smaller meeting would thus make it public property in this regard. Even the mere submission of an abstract or manuscript may prevent you from obtaining a patent and may thus make a patent impossible as well as the commercialization of the product. What once was a "brilliant idea" that might mean enormous benefits to mankind, might thus be "killed" by its inventor due to insufficient knowledge in immaterial rights. In many countries, the scientists own their data or invention themselves, although the research was supported financially by the university or by other funds. In these cases it is even more important that the scientist has proper education in these matters not to jeopardize the transfer of the idea from the laboratory to the patient.
I think that anybody related to research that may result in a product, treatment modality or similar should carefully investigate the situation at their affiliation and also try to assimilate sufficient knowledge to be able to handle their data in a proper way. One easy way to start is to visit the homepage of the United States patent and trademark office (www. uspto.gov). Besides from the satisfaction that the research may be made useful to patients, the successful transferral of research data into product may of course also result in royalty for the inventor which may be a welcome support to the continuous fight for research resources as we all are aware of.
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